Clinical Trial: Phase I, Open-labeled, Dose-escalation, Dose-expansion Study Evaluating the Safety, Tolerance, Pharmacokinetics, and Activity of IUAb190708 in Patients With Advanced or Recurrent Solid Tumors

U.S., May 14 -- ClinicalTrials.gov registry received information related to the study (NCT07584954) titled 'Phase I, Open-labeled, Dose-escalation, Dose-expansion Study Evaluating the Safety, Tolerance, Pharmacokinetics, and Activity of IUAb190708 in Patients With Advanced or Recurrent Solid Tumors' on May 06.

Brief Summary: This study is to evaluate a novel cytotoxic anti-PD-L1, IUAb190708, for the treatment of tumor

Study Start Date: June 18, 2024

Study Type: INTERVENTIONAL

Condition: Solid Tumor Cancer Solid Tumor Cancer Treatment With Immunotherapy

Intervention: DRUG: IUAb190708, a cytotoxic antibody

a novel cytotoxic anti-PD-L1 antibody

Recruitment Status: RECRUITING

Sponsor: Jun Zhou

Information provided by (Responsible Par...